Case studies from M.D. Anderson Cancer Center report dramatic reductions in PSA levels following treatment with Zyflamend and/or metformin (an activator of AMPK) in patients whose prostate cancer no longer responds to a variety of standard therapies [9], an effect also observed in our recent clinical trial with prostate cancer patients undergoing radical prostatectomy [44]. Here, KLK3 is linked to prostate cancer.